天津科学技术出版社

先天免疫细胞在 CAR-T 治疗中的作用研究进展

查晨宇 1,2,王迎 1,2*
作者信息
  1. 1 中国医学科学院血液病医院(中国医学科学院血液学研究所),血液与健康全国重点实验室, 国家血液系统疾病临床医学研究中心,细胞生态海河实验室,天津 300020
  2. 2 天津医学健康研究院,天津 301600
* 通信作者

摘要

嵌合抗原受体T(CAR-T)细胞疗法在血液系统恶性肿瘤治疗中取得了突破性进展,但其长期疗效仍面临细胞持久性不足、肿瘤微环境抑制等多重挑战。近年来研究显示,CAR-T细胞的功能受到宿主先天免疫系统的深刻调控,二者之间存在复杂的相互作用网络。本综述旨在系统阐述先天免疫细胞在CAR-T治疗中的双重角色,总结通过靶向或重编程先天免疫细胞以增强CAR-T疗效的最新策略,并对未来协同先天与适应性免疫的下一代CAR-T疗法发展进行展望。


Research progress on the role of innate immune cells in CAR-T therapy

Chenyu ZHA 1,2, Ying WANG 1,2,*
Author Information
  1. 1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
  2. 2 Tianjin Institutes of Health Science, Tianjin 301600, China
* Corresponding author

Abstract

Chimeric antigen receptor T (CAR-T) cell therapy has achieved breakthrough progress in the treatment of hematologic malignancies, yet its long-term efficacy remains challenged by issues such as insufficient cell persistence and the immunosuppressive tumor microenvironment. Recent studies have revealed that CAR-T cell function is profoundly regulated by the host innate immune system, forming a complex interactive network between the two. This review systematically elucidates the dual roles of innate immune cells in CAR-T therapy, summarizes the latest strategies to enhance CAR-T efficacy by targeting or reprogramming innate immune cells, and offers perspectives on the development of next-generation CAR-T therapies that harness both innate and adaptive immunity.

利益冲突:作者均声明无利益冲突

再生医学研究 Copyright © 2026. All Rights Reserved